SGS

Global Testing — GC-MS analytics.

Country: Switzerland

Coverage

	CN	EU	IN	US
finance-investment	✓	✓	—	✓
market-access-commercial	✓	✓	—	✓
regulatory-legal	✓	✓	✓	✓

Regulatorsemafdaechadefraefsausda-aphisnmpaepa

Verifiable facts

Fact	Value	Source
Revenue	CHF 6.945 billion (2025-12-31)	esgdistrict.lecho.be · umbrex.com · marketscreener.com · sgs.com
Headcount	over 100,000 employees (2025-12-31)	esgdistrict.lecho.be · marketscreener.com · sgs.com
Production site	over 2,500 laboratories and business facilities in over 115 countries (2025-12-31)	umbrex.com · marketscreener.com · sgs.com
Certification	ISO/IEC 17025 accredited laboratories and other industry-standard certifications (2025-12-31)	env.sgs.com · marketscreener.com · sgs.com
Regulatory approval	US EPA method validations including EPA 1633 and EPA 16130, and NELAP/DoD ELAP accreditations (2025-12-31)	env.sgs.com · setac.confex.com · sgs.com
Capacity	Quadrupled PFAS testing capacity in North America (2024-12-31)	sgs.com

Independent sources: env.sgs.com · esgdistrict.lecho.be · marketscreener.com · setac.confex.com · sgs.com · umbrex.com

Technologies

Name	Cluster	Risk
Biodiversity credits	finance-investment	Low	→
Distributor compliance auditing (GDP)	regulatory-legal	Low	→
Ecological risks of synthetic biology	regulatory-legal	Medium	→
FSMA and HACCP certification for bio-food	regulatory-legal	Medium	→
GMP consulting for nutraceuticals	regulatory-legal	Low	→
REACH compliance for bio-chemicals	market-access-commercial	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.